Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is currently conducting a Phase 3 clinical ...

Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a Phase 3 clinical study ...

The UP-AA clinical program includes 2 studies assessing the safety and efficacy of upadacitinib in adults and adolescent patients with severe alopecia areata.

US pharma major AbbVie recently announced top-line results from one of two parallel studies of the pivotal Phase III UP-AA ...

In July 2025, AbbVie announced top line results from one of two parallel studies of the Phase III UP-AA trial evaluating upadacitinib in alopecia areata (AA).

Upadacitinib 15 mg — but not 7.5 mg — alongside a glucocorticoid taper demonstrated superior efficacy to placebo with a glucocorticoid taper in giant cell arteritis, according to data ...

Upadacitinib demonstrated superiority versus dupilumab in primary endpoint of simultaneous achievement of near complete skin clearance (EASI 90) and no to little itch (WP-NRS 0/1)at Week 161 ...

Upadacitinib, a JAK1 inhibitor, is superior to adalimumab and placebo at improving signs, symptoms and physical function among patients with rheumatoid arthritis who have had an inadequate ...

Adult patients with moderate to severe atopic dermatitis (AD) had a 1-year and 1.5-year upadacitinib drug survival of 91.5% and 80.2%, respectively.

Upadacitinib 15 mg is also approved by the European Commission for adults with RA, psoriatic arthritis, and ankylosing spondylitis. The European Commission also approved the drug for moderate to ...

Rheumatology > Arthritis Success for Upadacitinib in PsA, Despite Concerns — JAK inhibitor nabs new indication after FDA called for boxed warnings on the class by Nancy Walsh, Contributing ...

Both upadacitinib and abatacept have demonstrated efficacy in rheumatoid arthritis. To compare them head-to-head, the investigators conducted a double-blind trial at 120 sites in 28 countries ...